Effect of an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer Patients

Breast Cancer Clinical Trial

Official title:

Pragmatic, Controlled, Single-Center, Randomized Clinical Trial to Evaluate the Effect of Supplementation With an Amino Acids and Flavonoids Containing FSMP on Chemotherapy Toxicity, Nutritional Status and Quality of Life in Breast Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05968677
• Other study ID #: SELECT-BC
• Status: Recruiting
• Phase: N/A
• Start date: August 4, 2023
• Est. completion date: August 2025

Study information

• Verified date: September 2023
• Source: Flavolife Srl
• Contact: Paolo Pedrazzoli, MD
• Phone: +390382501659
• Email: p.pedrazzoli[@]smatteo.pv.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the effect of a Food for Special Medical Purposes (FSMP) mainly containing amino acids and flavonoids in combination with nutritional counseling, versus nutritional counseling alone, on chemotherapy toxicity, nutritional status and quality of life in patients with breast cancer.

The main questions it aims to answer are:

• can this dietary supplementation affect the nutritional status of breast cancer patients?

• can this dietary supplementation have any beneficial effect on chemotoxicity? Participants will be asked to undergo nutritional counseling and to take the study product every day for 12 weeks.

Researchers will compare a similar group of participants only receiving the nutritional counseling to see if any difference occurs.

Description:

Participants will be selected at the first oncological visit at the Outpatient Clinics or the Department of Medical Oncology of the IRCCS Policlinico San Matteo of Pavia. The doctor, evaluated the inclusion and exclusion criteria, will propose patient to participate in the study and, after obtaining informed consent, will proceed with enrollment. On the first day of chemotherapy, participants will undergo an oncological and nutritional examination, with collection of anthropometric data, assessment of body composition, assessment of quality of life through special validated questionnaires, blood sampling for blood chemistry tests and urine collection. Participants in the treated group will receive a supply of the FSMP to take home. At check-up visits, the participant's nutritional status and any adverse events will be assessed, other than adherence to treatment by delivery of empty product boxes and chemotherapy compliance. Blood chemistry tests will be repeated at 6 weeks after the first chemotherapy cycle and 3 weeks after the last chemotherapy cycle (follow-up period).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosis of non-metastatic ductal breast cancer

• Post-menopausal women

• Chemotherapy with Doxorubicin or Epirubicin, with or without Cyclophosphamide, scheduled as adjuvant or neo-adjuvant

• Written informed consent

• Independent oral feeding

• Must be able to carry out periodic visits

Exclusion Criteria:

• Artificial feeding

• Eastern Cooperative Oncology Group (ECOG) performance status >2

• Impossibility to take the foreseen measurements

• Other tumor pathologies

• Previous therapy with Doxorubicin or Epirubicin

• Ongoing treatment with molecular targeted therapies

• Previous chronic renal, hepatic or cardiac insufficiency

• History of mental disorders

• Known allergies or intolerances to any study product ingredient

• Participation in other interventional clinical trials in the past three months

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Dietary Supplement:
• FSMP
Food for Special Medical Purposes specifically formulated for the dietary management of malnourished patients following therapeutic treatments such as chemo and radiotherapy

Other:
• Nutritional counseling
Participant's nutritional status will be evaluated, anthropometric data will be collected (weight, height, BMI), body composition will be evaluated (FFMI, BIVA) and a food diary will be compiled

Locations

Country	Name	City	State
Italy	IRCSS San Matteo University Hospital Foundation	Pavia

Sponsors (1)

Lead Sponsor	Collaborator
Flavolife Srl

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change from baseline in High-Sensitivity Troponin Levels as a serological marker of chemotherapy cardiotoxicity	The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model	0, 6, 12 weeks
Secondary	Mean change from baseline in weight, Body Mass Index (BMI) and Fat Free Mass Index (FFMI)	Participant's weight in kilograms and height in meters will be combined to report BMI and FFMI in kg/m^2	0, 3, 6, 9, 12 weeks
Secondary	Mean change from baseline in Phase Angle	Participant's body composition will be evaluated through measurement of the phase angle which represents the relationship between resistance and capacitive reactance of the body and bioimpedance diagnostics	0, 3, 6, 9, 12 weeks
Secondary	Mean change from baseline in Bioelectrical Impedance Vector Analysis (BIVA)	Participant's water and nutritional status will be evaluated	0, 3, 6, 9, 12 weeks
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Proportion of participants with adverse events of any type and specifically haematological, cardiac, gastrointestinal, hepatobiliary, metabolic, psychiatric, renal and urinary types, distinguishing between grade 1-2, grade 3-4 and grade 5.; Furthermore, the proportion of participants who discontinue chemotherapy treatment and the change in the number of participants who reduce their chemotherapy dose during the treatment	3, 6, 9, 12 weeks
Secondary	Mean change from baseline in Interleukine-6 levels	The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model	0, 6, 12 weeks
Secondary	Mean change from baseline Interleukine-1 beta levels	The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model	0, 6, 12 weeks
Secondary	Mean change from baseline in C-reactive Protein levels	The comparison of changes from baseline will be performed using a generalized linear regression model, adjusting for the baseline value of the biomarker. The difference in averages between groups and the relative range of confidence of 90 percent will be derived from the model	0, 6, 12 weeks
Secondary	Participant's perception of her physical and mental state	Comparison of the total average values resulting from the compilation of two validated oncological questionnaires, which include questions with scores from 1 to 4, where in general higher scores mean a worse outcome	0, 12 weeks